Mizuho Securities Starts Freeline (FRLN) at Buy
- Wall Street slips off record highs, Tesla drops after fatal crash
- IBM (IBM) Tops Q1 EPS by 14c, Revenue Beats
- Tesla's (TSLA) Musk says data logs from crashed vehicle show Autopilot was not enabled, car did not purchase FSD
- Bitcoin (BTC) Price Fell 20% Off the Highs Over the Weekend as Markets Got 'Too Excited' About Coinbase (COIN), Says Mike Novogratz
- GameStop (GME) CEO Gets the Axe as Ryan Cohen Continues to Make His Mark, Analyst Says Co. Will Likely Look to Tech Sector for New Hires
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Mizuho Securities analyst Difei Yang initiates coverage on Freeline (NASDAQ: FRLN) with a Buy rating and a price target of $27.00.
The analyst comments "Freeline's technology platform uses a proprietary AAV capsid to enable higher transduction efficiency in the liver, which we believe could enable "normalization" of protein deficiencies in hemophilia as well as lysosomal storage disorders. Our proprietary survey suggests strong commercial potential for the company's lead program in Hemophilia B given superior factor activity levels achieved by patients vs. competitors. Confirmation of efficacy/safety is likely to be an important catalyst in 2021/2022. Applicability of Freeline's platform in lysosomal storage disorders could offer additional upside, and we see a good opportunity in Gaucher disease where gene therapy competition is currently limited."
Shares of Freeline closed at $13.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: UPDATE: Wells Fargo Starts FuelCell Energy (FCEL) at Underweight
- Ambuja Cements Ltd. (ACEM:IN) PT Raised to INR380 at Citi
- Oil Search Ltd. (OSH:AU) (OISHY) PT Lowered to AUD3.62 at CLSA
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!